All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373)

NICE GUIDANCE ISSUED DECEMBER 2015

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 0812 – March 2012

Adalimumab (Humira®▼)

Limited submission by: Abbott Laboratories Ltd

Recommendation of AWMSG

Adalimumab (Humira®▼) in combination with methotrexate is recommended as an option for use within NHS Wales for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. Adalimumab (Humira®▼) can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

AWMSG is of the opinion that adalimumab (Humira®▼) is suitable for specialist only prescribing within NHS Wales for the above indication.

Additional note:

Adalimumab (Humira®▼) for the above indication met the following criteria for a limited submission:

- A minor licence extension.
- Estimated small difference in cost compared to the comparator.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay perspective and discussions at AWMSG.

This recommendation was ratified by the Minister for Health and Social Services on 25th April 2012 and will be considered for review in April 2015.